OBJECTIVE: Polyhydramnios involves about 1-2% of overall pregnancies. The objective of our study was to analyze the risk for clinically significant chromosomal microarray analysis (CMA) findings in this common sonographic abnormality. STUDY DESIGN: Data from all CMA analyses performed due to polyhydramnios between January 2013 and September 2017 were retrospectively obtained from the Ministry of Health database. Risk estimation was performed comparing the rate of abnormal microarray findings to two control populations, based on a systematic review of 9272 pregnancies and a large local cohort of 5541 fetuses with normal ultrasound. Subgroup analyses were performed by the degree of polyhydramnios, week of diagnosis, and presence of associated sonographic anomalies. RESULTS: Of 498 pregnancies with isolated polyhydramnios, 17 (3.4%) clinically significant CMA aberrations were noted. Pregnancies with mild polyhydramnios (amniotic fluid index (AFI) 25-29.9 or maximal vertical pocket 8-11.9 cm, 124 cases) did not yield an increased risk for abnormal CMA results compared to control populations. Similarly, the risk was not increased in pregnancies with AFI below 97.5 percentile for gestational age (n¼54), as well as in cases diagnosed above 34 weeks (n¼75). However, pregnancies with isolated moderate and severe polyhydramnios, AFI above 97.5 percentile or cases diagnosed before 34 weeks were associated with significantly increased risk for clinically significant CMA findings. Of 64 cases of non-isolated polyhydramnios (most frequently associated with cardiovascular and brain anomalies), 5 (7.8%) % abnormal CMA findings were noted, a significantly higher rate compared to both control populations. In addition, non-isolated cohort yielded a significantly higher ratio of karyotype-detectable to submicroscopic aberrations (4/5, or 80.0%), compared to isolated cases (2/17, or 11.8%, p¼0.0026). CONCLUSION: An extensive anatomical sonographic survey must be performed in pregnancies with polyhydramnios, with consideration of fetal echocardiography. CMA testing should be recommended in pregnancies with polyhydramnios above 97.5 percentile for gestational age, cases diagnosed before 34 weeks, or those associated with additional sonographic findings, whereas mild or late polyhydramnios does not seem to increase the rate of chromosomal aberrations compared to pregnancies with normal ultrasound. OBJECTIVE: To conduct a pilot validation study for cell-based NIPT to assess the feasibility for performing a more rigorous CLIA validation. STUDY DESIGN: Thirty mL venous blood samples (EDTA) were studied from 42 singleton pregnancies (GA 8w-20w) including both low & high risk for chromosomal or other genetic abnormalities, of which 19 also underwent amnio or CVS. Fetal cells were recovered using RBC lysis and fetal cell magnetic bead enrichment with one internally developed and three commercial antibodies. Cells were identified as putatively fetal based on morphology and staining pattern, and picked individually for subsequent whole genome amplification and whole genome next generation sequencing (NGS) Poster Session V ajog.org (1-10 million reads). All NGS data were scored by two blinded ABMGG certified lab directors. Female cells were genotyped to confirm fetal origin. RESULTS: An average of 5.4 putative fetal cells (range 1-23) per case were microscopically identified. After processing and copy number analysis, a mean of 2.2 cells per case (range 0-5) were found to be scorable for aneuploidy with 65% of those also scorable for deletions (>1Mb) ( Table 1) . Some cells were excluded if they were maternal (8%) or of poor quality (usually apoptotic, 12%). Some cells were in S phase (8%) and could be scored for aneuploidy but not deletion. There were 7 cases of aneuploidy (an example is illustrated in Figure 1 ), and 30 with normal results. For the 25 cases with 2 scorable cells, there was never discordance between multiple cells from the same case relative to abnormality or normality. All cell-based NIPT agreed with other available data from amnio or CVS, except in one case of likely placental mosaicism. One case of balanced translocation found on CVS was scored normal by cell-based NIPT. CONCLUSION: These data are promising for our goal of obtaining an adequate result in 95% of the cases in the near future. Our ongoing and future work is focused on optimizing immuno-enrichment, increasing the blood volume to 40 mL, prompt redraw if less than three cells are recovered in the first sample, and improving informatics for better single cell analysis. The current method is laborintensive and technically challenging, but is rapidly improving with potential for future automation of various steps. Cell-based NIPT is a rapidly evolving technique with strong potential as a clinical test in the near future.
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901 High fetal fraction on first trimester cell free DNA aneuploidy screening and adverse perinatal outcomes.
Lydia L. Shook, Mark A. Clapp, Penelope A. Roberts, Sarah N. Bernstein, Ilona T. Goldfarb Massachusetts General Hospital, Boston, MA OBJECTIVE: Elevated levels of fetal cell free DNA (cfDNA) in maternal circulation have been observed in pathologic conditions such as preeclampsia and preterm birth at the time of diagnosis. Evidence is conflicting, however, on the clinical significance of a high fetal fraction (FF) result on routine aneuploidy screening. We aimed to test the hypothesis that high FF is associated with adverse perinatal outcomes in women with an otherwise normal first trimester cfDNA result. STUDY DESIGN: This is a single-institution retrospective cohort study of women who underwent cfDNA aneuploidy screening at <14 weeks' gestation and delivered a viable infant between July 2016 and June 2018. Women with a multiple gestation, abnormal cfDNA result, or low fetal fraction (<5%ile) were excluded. The primary outcome of interest was preterm birth <37 weeks' gestation; secondary outcomes were hypertensive disorders of pregnancy, low birth weight 10%ile and 5%ile using growth curves by Oken et al., and abruption. High FF was defined as >95%ile. RESULTS: Of 1,933 women that met inclusion criteria, the mean FF was 10.4%, and a FF >16.5% was considered high (n¼101). Median maternal age of the study population was 36, consistent with indication for aneuploidy screening. Compared to women with normal FF, women with high FF had significantly lower BMI (21.6 vs 24.1 kg/m 2 , P<0.001) and were more likely to be multiparous (43% vs 29%, P<0.01). We found no significant difference in the rate of preterm birth <37 weeks' gestation between groups, though results were limited by sample size. However, women with high FF were more likely to have a low birth weight infant 5%ile (OR 2.4[1.1-5.4]), which maintained significance after controlling for gestational age at the time of cfDNA testing, BMI, maternal age, and parity. High FF was also associated with low birth weight 10%ile (OR 1.9[1.1-3.5]), though this result did not maintain significance after controlling for confounders. There was no significant difference in rates of abruption or hypertensive disorders of pregnancy between groups. CONCLUSION: High FF in the first trimester is associated with low birth weight infants in patients with otherwise negative aneuploidy screening results. Further investigation into the clinical implications of a high FF result is warranted. OBJECTIVE: Cell-free DNA (CfDNA) screening in morbidly obese (body mass index 40 kg/m2) women has an increased no result rate due to lower fetal fraction. Conventional serum screening is not limited by maternal weight. The aim of this project was to estimate the costeffectiveness of trisomy 21 (T21) screening in morbidly obese women using cfDNA compared to traditional serum integrated screening. STUDY DESIGN: Using TreeAge software, we created a decision-analytic model to compare two prenatal screening strategies for fetal trisomy 21 detection: (1) Serum integrated screening (INT) with first trimester PAPP-A and beta-hCG and second trimester quad
